Medicus Pharma Ltd Ordinary Shares MDCX 深 沪
等待开盘 11-05 09:30:00 美东时间
2.20
-0.140
-5.98%
华盛通- 最 高2.35
- 今 开2.29
- 成交量 27.96万股
- 最 低 2.15
- 昨 收 2.34
- 总市值 3919.59万
- 52周最高 8.94
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 1.7901
- 委 比 44.63%
- 总股本 1781.63万
- 历史最高 8.94
- 量 比 1.06
- 振 幅 8.55%
- 历史最低 1.7901
- 每 手 1
- 风险率 1.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Medicus Pharma Partners With Gorlin Syndrome Alliance To Enhance Access To SKINJECT For Gorlin Syndrome Patients
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
10-29 19:34
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Medicus Pharma collaborates with Gorlin Syndrome Alliance to advance access to SKINJECT™, a novel therapy for Gorlin syndrome patients with basal cell carcinomas. SKINJECT™ uses microneedle arrays to deliver doxorubicin, targeting localized treatments for skin cancers. The collaboration aims to establish an Expanded Access IND Program, collecting real-world data to support future regulatory filings. Gorlin syndrome affects 1 in 31,000 people, cau...
10-29 11:30
Medicus Pharma Begins UAE Trial for Non-Invasive Skin Cancer Treatment
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
10-22 19:35
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
09-26 20:10
Medicus Pharma To Present Update On D-MNA And Teverelix Programs On Sept. 29 At Brookline Capital Markets
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation
09-24 19:43
Lockheed Martin Vectis™: Best in CCA Class Survivability
NATIONAL HARBOR, Md., Sept. 21, 2025 /PRNewswire/ -- Lockheed Martin Skunk Works® (NYSE: LMT) introduces Vectis, a Group 5 survivable and lethal collaborative combat aircraft (CCA) to advanc...
09-21 21:00
Medicus Pharma Appoints Carolyn Bonner as Acting CFO
Medicus Pharma Ltd ( ($MDCX) ) has shared an update. On September 12, 2025, Med...
09-13 05:25
Medicus Pharma Announces SKNJCT-004 Phase 2 Clinical Study, To Non-Invasively Treat BCC Of The Skin, Commences Patient Recruitment In Cleveland Clinic Abu Dhabi
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
09-08 19:33
Medicus Pharma Completes Equity Sales to Yorkville
An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma ...
08-23 04:59
